Skip to main content
. 2014 Dec 2;112(1):52–60. doi: 10.1038/bjc.2014.563

Figure 5.

Figure 5

Analysis of molecular markers. (A) Ki67 labelling index at baseline, day 14 and at the definitive surgery. Proliferation trend is reported for each patient. A significant reduction in mean average proliferation index is observed between baseline and day 14 (P=0.00001) and between baseline and end of treatment (P=0.031). (B) Immunohistochemistry demonstrating the expression of angiogenesis-related markers (CD31 and VEGF-A) in pre-treatment and post-treatment samples.